This disclosure provides, at least in part, a pharmaceutical product comprising setmelanotide or another pharmaceutical composition that has its primary mechanism of action at the MC4 receptor as an agonist and an excipient, e.g., a lipid excipient, and/or a pharmaceutically acceptable carrier. The pharmaceutical product described herein provides a sustained release of setmelanotide or another pharmaceutical composition, which may result in a more desirable pharmacokinetic and pharmacodynamic profile upon administration.本發明至少部分提供一種醫藥產品，其包含塞特諾肽(setmelanotide)或作為促效劑於MC4受體處發揮主要作用機制之另一醫藥組合物，及賦形劑(例如，脂質賦形劑)及/或醫藥上可接受之載劑。本文描述之醫藥產品提供塞特諾肽或另一醫藥組合物之持續釋放，此可在投與時導致更理想之藥物動力學及藥效動力學概況。
